Poster Abstract Session:
156. Resistance Mechanisms
Friday, October 9, 2015: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

-

Tracks: Adult ID

Presentations:
1174
Global Susceptibility Trends and Extended Spectrum Beta-lactamase (ESBL) Rates Among Proteus mirabilis: Results of the SMART 2010-2014 Analysis
Daryl Hoban, PhD ; Douglas Biedenbach, MS ; Meredith Hackel, PhD, MPH ; Dan Sahm, PhD
Posters
  • Merck P34_P mirabilis_Global_ESBL_IDSA 2015_V01_final [Read-Only].pdf (188.1 kB)
    • 1175
    The Activity of Ceftolozane/Tazobactam against Gram-negative Pathogens Isolated From Patients Hospitalized in Intensive Care Units in USA Hospitals (2013-2014)
    David J. Farrell, PhD ; Helio S. Sader, MD, PhD ; Mariana Castanheira, PhD ; Ronald N. Jones, MD
    Posters
  • 101102408_Farrell_L2c.pdf (357.3 kB)
    • 1176
    β-lactamase Characterization of Baseline Enterobacteriaceae (ENT) from a Phase 3 Trial of ceftazidime-avibactam (CAZ-AVI) for the Treatment of Infections Caused by CAZ-nonsusceptible (NS) Pathogens
    Rodrigo E. Mendes, PhD ; Mariana Castanheira, PhD ; Leah N. Woosley, BS ; Sarah E. Costello, BS ; Gregory G. Stone, PhD ; Robert K. Flamm, PhD ; Ronald N. Jones, MD
    1177
    Carbapenemases Found in Meropenem Non-Susceptible Enterobacteriaceae Collected as Part of the Tigecycline Evaluation Surveillance Trial (TEST) Program in 2011-2014
    Krystyna Kazmierczak, PhD ; Meredith Hackel, PhD, MPH ; Brian Johnson, BS ; Dan Sahm, PhD ; Heidi Leister-Tebbe, BSN
    Posters
  • Pfizer_P27_IDSA_Carbapenemases 2011-2014_v1_final [Read-Only].pdf (442.6 kB)
    • 1178
    Fluoroquinolone Resistance among Enterobacteriaceae from U.S. Medical Centers between 2011 and 2014
    Brian Johnson, BS ; Jack Johnson, MS, MBA ; Samuel Bouchillon, MD ; Meredith Hackel, PhD, MPH ; Dan Sahm, PhD ; Douglas Biedenbach, MS ; Heidi Leister-Tebbe, BSN
    Posters
  • Pfizer_P33_IDSA 2015_USA_FQR Enterics_v01_final [Read-Only].pdf (87.3 kB)
    • 1179
    basS mutations linked to colistin resistance (ColR) among Enterobacter cloacae
    Roberto Viau, MD ; Mark Adams, PhD ; Laura J. Rojas, MSc ; Robert Bonomo, MD ; Maria Virginia Villegas, MD, MSc, FIDSA
    Posters
  • poster-colR.pdf (730.6 kB)
    • 1180
    Is Ceftriaxone (CRO) Effective in Treating Ceftriaxone Resistant (CRO-R) Escherichia coli Urinary Tract Infections?
    Philip Lee, PharmD, BCPS ; Whitney (Yu-Hui) Hung, PharmD, BCPS (AQ-ID) ; David Peaper, MD, PhD ; Jeffrey Topal, MD
    1181
    Molecular Characterization of Piperacillin-Tazobactam (TZP) Resistant Escherichia coli Susceptible to Cephalosporins, Monobactams, and Carbapenems
    Jose R. Mediavilla, MPH, MBS ; Zachary Schneider, BA ; Chinedum Nwaigwe, HS ; Kalyan D. Chavda, MS ; Liang Chen, PhD ; Michael Satlin, MD, MS ; Stephen Jenkins, PhD ; David P. Nicolau, PharmD, FCCP, FIDSA ; Barry N. Kreiswirth, PhD
    1182
    Tackling Multidrug Resistance by Targeting Efflux in Pseudomonas aeruginosa
    Kelly Bachta, MD PhD ; John Mekalanos, PhD
    1183
    Assessment of Antibiotic Resistance Genes, Phenotypic Expression and Association with Antibiotic Exposure in Serial E. coli Isolates Recovered from Combat-Injured U.S. Military Service Members
    Katrin Mende, PhD ; Erik Snesrud, BS ; Fatma Onmus-Leone, MS ; Lakshmi Appalla, MS ; Mary Hinkle, M.D. ; Emil Lesho, DO, FIDSA ; Ping Li, MS ; Clinton K. Murray, MD, FIDSA ; David Tribble, MD, DrPH, FIDSA
    Posters
  • Poster 1183 - Mende et al sm.png (393.6 kB)
    • 1184
    The Activity of Tedizolid against Gram-positive Pathogens Isolated From Patients in USA Medical Centers: 2014 Surveillance
    David J. Farrell, PhD ; Robert K. Flamm, PhD ; Rodrigo E. Mendes, PhD ; Ronald N. Jones, MD
    Posters
  • 150100737 JMI_L1e.pdf (288.8 kB)
    • 1185
    Report of Linezolid Activity from the Linezolid Experience and Accurate Determination of Resistance (LEADER) Program for 2014: Monitoring Resistance Trends and Mechanisms
    Jennifer M. Streit, BS ; Robert K. Flamm, PhD ; James E. Ross, MBA ; Rodrigo E. Mendes, PhD ; Ronald N. Jones, MD ; Patricia a. Hogan, MBA
    Posters
  • IDWeek15 LEADER 1185.pdf (173.6 kB)
    • 1186
    Substitutions in LiaFSR and Enzymes Involved in Glycerophospholipid Metabolism Correlate with High-Level DAP-Resistance in vivo in E. faecium
    Jose Munita, MD ; Rafael Rios, MSc ; Jinnethe Reyes, PhD ; Truc Tran, PhamD ; Diana Panesso, PhD ; Dylan Smith, BS ; Sandra Rincon, MSc ; Lina Paola Carvajal, BSc ; Juan David Garavito, BSc ; Mateo Castellanos, BSc ; Javier Adachi, MD, FIDSA ; Cesar Arias, MD, PhD, FIDSA ; Lorena Diaz, PhD
    1187
    Acquired multidrug antifungal resistance in Candida lusitaniae during therapy
    Sandra Asner, MD, MSc ; Stefano Giulieri, MD ; Manuel Diezi, MD ; Oscar Marchetti, MD ; Dominique Sanglard, MD, PhD
    Posters
  • ID_week_2015_SAA.pdf (744.5 kB)
    • 1188
    The Anti-Respiratory Syncytial Virus (RSV) Nucleoside Analog, AL-8112, and its Orally Bioavailable Prodrug, AL-8176, Exhibit a High Barrier to the Emergence of Viral Resistance
    Jin Hong, PhD ; Hong Liu, PhD ; Joshua Taylor, BS ; Matthew Mcclure, MD ; Sushmita Chanda, PhD ; John Fry, RN ; Leo Beigelman, PhD ; Lawrence Blatt, PhD ; Julian Symons, D.Phil
    Posters
  • AL-8176_Viral Resistance_ID Week 2015_Hong_Print Version_JRD.pdf (391.9 kB)
    • 1189
    Analysis of GS-5806 Resistance Emergence in Human Healthy Adult Subjects Experimentally Infected with Respiratory Syncytial Virus (RSV)
    Robert Jordan, Ph.D. ; Kirsten Stray, B.S. ; Francisco Anderson, B.S. ; Michel Perron, Ph.D. ; Richard Mackman, Ph.D. ; Michael Miller, Ph.D. ; Hongmei Mo, Ph.D. ; Evguenia Svarovskaia, Ph.D. ; Ross Martin, B.S. ; Yan Xin, Ph.D. ; Srini Ramanathan, PhD ; Thomas O'riordan, M.D. ; Sandra Lewis, Ph.D. ; Xiaoming Li, Ph.D. ; Seth Toback, M.D. ; Jason Chien, M.D. ; John Sundy, M.D. ; John Devincenzo, MD ; Tomas Cihlar, Ph.D.
    Posters
  • Bio Jordan IDWeek 88x44@275-PrintReady.pdf (142.1 kB)

    • CME Credits:

    ACPE Credits:

    ACPE Number:


    See more of: Poster Abstract Session
    << Previous Session | Next Session >>

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.